LncRNA WWOX‑AS1 inhibits the proliferation, migration and invasion of osteosarcoma cells

Qu,Gang; Ma,Zhiqiang; Tong,Wenxian; Yang,Jiahui

doi:10.3892/mmr.2018.9058

LncRNA WWOX‑AS1 inhibits the proliferation, migration and invasion of osteosarcoma cells

Authors:
- Gang Qu
- Zhiqiang Ma
- Wenxian Tong
- Jiahui Yang
View Affiliations

Affiliations: Department of Osteology, The 161th Hospital of People's Liberation Army, Wuhan, Hubei 430010, P.R. China, Department of Oncology, The Fifth Hospital of Wuhan, Wuhan, Hubei 430050, P.R. China
Published online on: May 23, 2018 https://doi.org/10.3892/mmr.2018.9058
Pages: 779-788
Copyright: © Qu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently, numerous long non‑coding (lnc)RNAs have been revealed as serving important roles in human gene regulation. Previous studies have suggested that aberrant expression of lncRNAs is associated with cancer progression and metastasis. Previous studies have also demonstrated that decreased expression of WW domain‑containing oxidoreductase (WWOX) is associated with poor prognosis in numerous cancer types. However, the effect of WWOX antisense RNA 1 (WWOX‑AS1) in the development of cancer remains unknown. The aim of the present study was to investigate the role of WWOX‑AS1 in osteosarcoma. The expression levels of WWOX‑AS1 in human osteosarcoma cell lines and a normal osteoblastic cell line were investigated using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The results revealed that WWOX‑AS1 expression was downregulated in osteosarcoma tissues. Furthermore, the association between WWOX‑AS1 and the prognosis of patients with osteosarcoma was investigated using Kaplan‑Meier and log‑rank tests. The results suggested that patients exhibiting high WWOX‑AS1 expression demonstrated a greater overall survival compared with patients exhibiting low WWOX‑AS1 expression. In addition, overexpression and knockdown of WWOX‑AS1 was performed using transfection experiments and confirmed by RT‑qPCR in MG63 and SAOS2 cells, respectively. The results demonstrated that WWOX‑AS1 and WWOX expression were positively correlated. Furthermore, the results of the knockdown and overexpression functional experiments suggested that WWOX‑AS1 overexpression inhibited the proliferation, migration and invasion of MG63 cells, and knockdown of WWOX‑AS1 enhanced the proliferation, migration and invasion of MG63 cells in SAOS2 cells. In conclusion, the results of the present study suggested that WWOX‑AS1 may represent a potential biomarker and therapeutic target for the treatment of osteosarcoma.

View Figures

View References

1	McKenna WG, Barnes MM, Kinsella TJ, Rosenberg SA, Lack EE and Glatstein E: Combined modality treatment of adult soft tissue sarcomas of the head and neck. Int J Radiat Oncol Biol Phys. 13:1127–1133. 1987. View Article : Google Scholar : PubMed/NCBI
2	Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al: Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI
3	Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lee JT: Epigenetic regulation by long noncoding RNAs. Science. 338:1435–1439. 2012. View Article : Google Scholar : PubMed/NCBI
5	Nagano T and Fraser P: No-nonsense functions for long noncoding RNAs. Cell. 145:178–181. 2011. View Article : Google Scholar : PubMed/NCBI
6	Tsai MC, Spitale RC and Chang HY: Long intergenic noncoding RNAs: New links in cancer progression. Cancer Res. 71:3–7. 2011. View Article : Google Scholar : PubMed/NCBI
7	Fan H, Zhu JH and Yao XQ: Knockdown of long noncoding RNA PVT1 reverses multidrug resistance in colorectal cancer cells. Mol Med Rep. 2018. View Article : Google Scholar
8	An Q, Zhou L and Xu N: Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother. 103:415–420. 2018. View Article : Google Scholar : PubMed/NCBI
9	Zhou Q, Chen F, Fei Z, Zhao J, Liang Y, Pan W, Liu X and Zheng D: Genetic variants of lncRNA HOTAIR contribute to the risk of osteosarcoma. Oncotarget. 7:19928–19934. 2016.PubMed/NCBI
10	Chen F, Mo J and Zhang L: Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription. Tumour Biol. 37:13403–13412. 2016. View Article : Google Scholar : PubMed/NCBI
11	Li Z, Zhao L and Wang Q: Overexpression of long non-coding RNA HOTTIP increases chemoresistance of osteosarcoma cell by activating the Wnt/β-catenin pathway. Am J Transl Res. 8:2385–2393. 2016.PubMed/NCBI
12	Li W, Xie P and Ruan WH: Overexpression of lncRNA UCA1 promotes osteosarcoma progression and correlates with poor prognosis. J Bone Oncol. 5:80–85. 2016. View Article : Google Scholar : PubMed/NCBI
13	Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D and Bieche I: Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: Identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 67:3963–3969. 2007. View Article : Google Scholar : PubMed/NCBI
14	Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP and Cui H: Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 451:202–206. 2008. View Article : Google Scholar : PubMed/NCBI
15	Takayama K, Horie-Inoue K, Katayama S, Suzuki T, Tsutsumi S, Ikeda K, Urano T, Fujimura T, Takagi K, Takahashi S, et al: Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 32:1665–1680. 2013. View Article : Google Scholar : PubMed/NCBI
16	Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich W, Roland BC, et al: Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut. 63:881–890. 2014. View Article : Google Scholar : PubMed/NCBI
17	Han L, Kong R, Yin DD, Zhang EB, Xu TP, De W and Shu YQ: Low expression of long noncoding RNA GAS6-AS1 predicts a poor prognosis in patients with NSCLC. Med Oncol. 30:6942013. View Article : Google Scholar : PubMed/NCBI
18	Tong W, Yang L, Yu Q, Yao J and He A: A new tumor suppressor lncRNA RP11-190D6.2 inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells. Onco Targets Ther. 10:1227–1235. 2017. View Article : Google Scholar : PubMed/NCBI
19	Yan H, Tong J, Lin X, Han Q and Huang H: Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells. Mol Med Rep. 12:1783–1788. 2015. View Article : Google Scholar : PubMed/NCBI
20	Xie B, Zen Q, Wang X, He X, Xie Y, Zhang Z and Li H: ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling. Int J Oncol. 46:2057–2066. 2015. View Article : Google Scholar : PubMed/NCBI
21	Nowakowska M, Pospiech K, Lewandowska U, Piastowska-Ciesielska AW and Bednarek AK: Diverse effect of WWOX overexpression in HT29 and SW480 colon cancer cell lines. Tumour Biol. 35:9291–9301. 2014. View Article : Google Scholar : PubMed/NCBI
22	Li G, Sun L, Mu Z, Huang Y, Fu C and Hu B: Ectopic WWOX expression inhibits growth of 5637 bladder cancer cell in vitro and in vivo. Cell Biochem Biophys. 73:417–425. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhang N, Jiang Z, Ren W, Yuan L and Zhu Y: Association of polymorphisms in WWOX gene with risk and outcome of osteosarcoma in a sample of the young Chinese population. Onco Targets Ther. 9:807–813. 2016.PubMed/NCBI
24	Del Mare S and Aqeilan RI: Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. Sci Rep. 5:129592015. View Article : Google Scholar : PubMed/NCBI
25	Jawad MU and Scully SP: In brief: Classifications in brief: Enneking classification: Benign and malignant tumors of the musculoskeletal system. Clin Orthop Relat Res. 468:2000–2002. 2010. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
28	Zhang T, Li J, Yin F, Lin B, Wang Z, Xu J, Wang H, Zuo D, Wang G, Hua Y and Cai Z: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene. 36:6627–6639. 2017. View Article : Google Scholar : PubMed/NCBI
29	Liu X, Xiu LJ, Jiao JP, Zhao J, Zhao Y, Lu Y, Shi J, Li YJ, Ye M, Gu YF, et al: Traditional Chinese medicine integrated with chemotherapy for stage IV non-surgical gastric cancer: A retrospective clinical analysis. J Integr Med. 15:469–475. 2017. View Article : Google Scholar : PubMed/NCBI
30	Mondal J, Das J, Shah R and Khuda-Bukhsh AR: A homeopathic nosode, Hepatitis C 30 demonstrates anticancer effect against liver cancer cells in vitro by modulating telomerase and topoisomerase II activities as also by promoting apoptosis via intrinsic mitochondrial pathway. J Integr Med. 14:209–218. 2016. View Article : Google Scholar : PubMed/NCBI
31	Adaramoye O, Erguen B, Oyebode O, Nitzsche B, Höpfner M, Jung K and Rabien A: Antioxidant, antiangiogenic and antiproliferative activities of root methanol extract of Calliandra portoricensis in human prostate cancer cells. J Integr Med. 13:185–193. 2015. View Article : Google Scholar : PubMed/NCBI
32	Wang X, Wang N, Cheung F, Lao L, Li C and Feng Y: Chinese medicines for prevention and treatment of human hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. J Integr Med. 13:142–164. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zang QQ, Zhang L, Gao N and Huang C: Ophiopogonin D inhibits cell proliferation, causes cell cycle arrest at G2/M, and induces apoptosis in human breast carcinoma MCF-7 cells. J Integr Med. 14:51–59. 2016. View Article : Google Scholar : PubMed/NCBI
34	Wahlestedt C: Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov Today. 11:503–508. 2006. View Article : Google Scholar : PubMed/NCBI
35	Faghihi MA and Wahlestedt C: Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol. 10:637–643. 2009. View Article : Google Scholar : PubMed/NCBI
36	Yelin R, Dahary D, Sorek R, Levanon EY, Goldstein O, Shoshan A, Diber A, Biton S, Tamir Y, Khosravi R, et al: Widespread occurrence of antisense transcription in the human genome. Nat Biotechnol. 21:379–386. 2003. View Article : Google Scholar : PubMed/NCBI
37	Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, Lee SH, Gaudio E, Zanesi N, Jones KB, DeYoung B, et al: Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression. Cancer Res. 70:5577–5586. 2010. View Article : Google Scholar : PubMed/NCBI
38	Del Mare S, Kurek KC, Stein GS, Lian JB and Aqeilan RI: Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma. Am J Cancer Res. 1:585–594. 2011.PubMed/NCBI
39	Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S and Olsen BR: Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. Mech Dev. 106:97–106. 2001. View Article : Google Scholar : PubMed/NCBI
40	Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS and Lian JB: The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol. 25:8581–8591. 2005. View Article : Google Scholar : PubMed/NCBI
41	Wang X, Manner PA, Horner A, Shum L, Tuan RS and Nuckolls GH: Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage. Osteoarthritis Cartilage. 12:963–973. 2004. View Article : Google Scholar : PubMed/NCBI
42	Lim M, Zhong C, Yang S, Bell AM, Cohen MB and Roy-Burman P: Runx2 regulates survivin expression in prostate cancer cells. Lab Invest. 90:222–233. 2010. View Article : Google Scholar : PubMed/NCBI
43	van der Deen M, Akech J, Lapointe D, Gupta S, Young DW, Montecino MA, Galindo M, Lian JB, Stein JL, Stein GS and van Wijnen AJ: Genomic promoter occupancy of runt-related transcription factor RUNX2 in osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem. 287:4503–4517. 2012. View Article : Google Scholar : PubMed/NCBI
44	Elbashir SM, Harborth J, Weber K and Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 26:199–213. 2002. View Article : Google Scholar : PubMed/NCBI